<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495247</url>
  </required_header>
  <id_info>
    <org_study_id>CBEZ235B2101</org_study_id>
    <secondary_id>2011-002400-32</secondary_id>
    <nct_id>NCT01495247</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, open-label, phase Ib/ II study (two parts) with patients&#xD;
      that have locally advanced or metastatic HER2 negative breast cancer. The first part (phase&#xD;
      Ib) will investigate the MTD / Recommended Phase 2 Dose (RP2D) of the combination therapy of&#xD;
      BEZ235 twice daily (b.i.d.) and weekly paclitaxel using a Bayesian model. When MTD/ RP2D is&#xD;
      established the second part (phase II) will start. Phase II will evaluate the efficacy and&#xD;
      the safety of weekly paclitaxel alone compared to weekly paclitaxel plus BEZ235 bid.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study did not meet Phase Ib primary objective to establish the maximum tolerated&#xD;
    dose/recommended dose for Phase II&#xD;
  </why_stopped>
  <start_date type="Actual">January 30, 2012</start_date>
  <completion_date type="Actual">May 19, 2014</completion_date>
  <primary_completion_date type="Actual">May 19, 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase lb: Dose Limiting Toxicities (DLTs) the first cycle of treatment</measure>
    <time_frame>At first treatment intake (Cycle 1 Day 1 = C1D1), C1D8, C1D15, C1D22 and C2D1 [a cycle = 4 weeks = 28 days]</time_frame>
    <description>DLT is defined as treatment-related toxicity (classified according Common Toxicity Criteria for Adverse Events (CTCAE) Version 4) occurring during the first 28 treatment days and meeting specific protocol-predefined criteria.&#xD;
The information will be integrated in a Bayesian logistic regression model with overdose control to estimate the maximum tolerated dose (MTD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase lb: Frequency and severity of adverse events</measure>
    <time_frame>At screening, every week (C1D1, C1D8, C1D15, C1D22, C2D1, C2D8, etc.) until 30-45 days after treatment discontinuation [estimated time frame: 18 months].</time_frame>
    <description>Incidence of adverse events (based on CTCAE Version 4) summarized by system organ class and/or preferred term, severity and relation to study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase lb: Progression free survival (PFS)</measure>
    <time_frame>At first treatment intake, every 8 weeks (C3D1, C5D1, C7D1, etc.) until disease progression or death for any cause [estimated time frame: 18 months].</time_frame>
    <description>PFS is defined as the time from start of treatment to objective tumor progression or death from any cause. Radiological assessments will be performed every 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase lb: Overall Response Rate (ORR)</measure>
    <time_frame>At first treatment intake, every 8 weeks (C3D1, C5D1, C7D1, etc.) during the study [estimated time frame: 18 months].</time_frame>
    <description>Proportion of patients with a best overall response of CR or PR according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase lb: Clinical Benefit Rate (CBR)</measure>
    <time_frame>At first treatment intake, every 8 weeks (C3D1, C5D1, C7D1, etc.) during the study [estimated time frame: 18 months].</time_frame>
    <description>Proportion of patients with a best overall response of CR, PR or SD with a duration of 24 weeks or longer according to RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Inoperable Locally Advanced Breast Cancer</condition>
  <condition>Metastatic Breast Cancer (MBC)</condition>
  <arm_group>
    <arm_group_label>BEZ235 100 mg bid + paclitaxel 80 mg (phase lb)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of oral BEZ235 100 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEZ235 200 mg bid + paclitaxel 80 mg (phase lb)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of oral BEZ235 200 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEZ235</intervention_name>
    <description>Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.</description>
    <arm_group_label>BEZ235 100 mg bid + paclitaxel 80 mg (phase lb)</arm_group_label>
    <arm_group_label>BEZ235 200 mg bid + paclitaxel 80 mg (phase lb)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.&#xD;
BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts.</description>
    <arm_group_label>BEZ235 100 mg bid + paclitaxel 80 mg (phase lb)</arm_group_label>
    <arm_group_label>BEZ235 200 mg bid + paclitaxel 80 mg (phase lb)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (phase lb):&#xD;
&#xD;
          -  Females with Breast cancer that is histologically or cytologically confirmed, HER2&#xD;
             negative and locally advanced or metastatic as confirmed by radiology&#xD;
&#xD;
          -  ECOG performance status 0 and 1&#xD;
&#xD;
          -  Adequate bone marrow and organ function&#xD;
&#xD;
        Exclusion Criteria (Phase lb):&#xD;
&#xD;
          -  Previous treatment with PI3K and/or mTOR inhibitors&#xD;
&#xD;
          -  Symptomatic Central Nervous System (CNS) metastases&#xD;
&#xD;
          -  Concurrent malignancy or malignancy in the last 5 years prior to start of study&#xD;
             treatment&#xD;
&#xD;
          -  Wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days&#xD;
             prior to starting study drug&#xD;
&#xD;
          -  Active cardiac disease (e.g. LVEF less than institutional lower limit of normal, QTcF&#xD;
             &gt; 480 msec, unstable angina pectoris, ventricular, supraventricular or nodal&#xD;
             arrhythmias)&#xD;
&#xD;
          -  Inadequately controlled hypertension&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of BEZ235 and/or paclitaxel&#xD;
&#xD;
          -  Treatment at start of study treatment with drugs with a known risk to induce Torsades&#xD;
             de Pointes, moderate and strong inhibitors or inducers of isoenzyme CYP3A4, warfarin&#xD;
             and coumadin analogues, LHRH agonists&#xD;
&#xD;
          -  Sensitivity to paclitaxel treatment&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Pregnant or nursing (lactating) woman&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Herblain Cédex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13703</url>
    <description>Results for CBEZ235B2101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <disposition_first_submitted>August 20, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 27, 2020</disposition_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced</keyword>
  <keyword>metastatic</keyword>
  <keyword>breast cancer</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>PI3K pathway</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>mTOR inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Dactolisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

